Battery Icon

Latest Presentation

Corporate Presentation

The Viveve PURSUIT Trial is a pivotal U.S. Stress Urinary Incontinence trial that is now fully enrolled

Completion of subject follow-up visits is anticipated by the end of 2022, and topline results will be reported shortly thereafter.

Read More

Pivotal U.S. Investigational Device Exemption (IDE) cleared trial

PURSUIT is a randomized, double-blinded, sham-controlled, IDE-cleared trial that enrolled 415 subjects with moderate SUI at approximately 30 study sites in the United States. Subjects were randomized in a 2:1 ratio to the active Viveve treatment or an inert sham treatment.

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Company Overview

Viveve Medical, Inc. (Viveve), is a women's health company focused on the treatment of female stress urinary incontinence (SUI). Based in Englewood, Colorado, the company is conducting a pivotal U.S. clinical trial called PURSUIT, using its novel, dual-energy treatment for SUI in women. The internationally patented Viveve® System incorporates Cryogen-cooled Monopolar Radiofrequency (CMRF) technology to uniformly provide an endovaginal treatment that is non-ablative. In the U. S., the Viveve System is cleared by the Food and Drug Administration (FDA) for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function and/or urinary incontinence. Viveve's current commercial and market development efforts focus on the U.S. and Asia Pacific regions targeting urogynecology, urology, and gynecology core specialties.

Viveve received FDA approval of its Investigational Device Exemption (IDE) application to conduct the multicenter, randomized, double-blinded, sham-controlled PURSUIT trial for improvement of SUI in women in July 2020, and FDA approval of its requested IDE protocol amendments in December 2020. The clinical trial was initiated in January 2021, and completion of subject enrollment was announced on December 14, 2021. Completion of subject follow-up visits is anticipated by the end of 2022, and topline results will be reported shortly thereafter. If positive, results from the PURSUIT clinical trial may support a new SUI indication in the U.S.

Stock Snapshot

IR Contacts

Company

Viveve Medical, Inc.
345 Inverness Drive South
Building B, Suite 250
Englewood, CO 80112
T: 720-696-8100
F: 720-696-8199
ir@viveve.com

Investor Relations

Amato and Partners
420 Lexington Avenue, 14th Floor
New York, New York 10107
T: (212) 430-0360
admin@amatoandpartners.com

Transfer Agent

VStock Transfer, LLC
Patricia Sumoza
Account Administrator - Team Supervisor
18 Lafayette Place
Woodmere, NY 11598
T: (212) 828-8436
F: (646) 536-3179
https://www.VStockTransfer.com